GHK-Cu: Dosing Protocols

Dosing Disclaimer#

The dosing information below is compiled from published research studies, cosmetic product formulations, and preclinical data. It is provided for educational and informational purposes only. GHK-Cu is not approved as a therapeutic agent by the FDA or any major regulatory authority. No official clinical dosing guidelines exist for therapeutic use. Topical cosmetic use follows manufacturer recommendations for individual products.

Topical Dosing and Formulation#

Concentration Ranges#

Topical application is the most common and best-characterized route of GHK-Cu administration. The concentration of GHK-Cu in topical products varies widely depending on the intended application:

Commercial anti-aging products typically contain GHK-Cu (listed as Copper Tripeptide-1 on ingredient labels) at concentrations ranging from 0.01% to 0.1% (100-1,000 parts per million). These concentrations represent the range most commonly encountered in commercially available serums, creams, and eye treatments. Some premium products may contain higher concentrations (up to 1%), though the concentration is not always disclosed on the product label.

Research formulations for wound healing studies have employed concentrations of 0.5% to 2% in hydrogel, cream, or ointment bases. These higher concentrations are used in preclinical animal wound models and have demonstrated accelerated wound closure, increased collagen deposition, and enhanced angiogenesis. At these concentrations, the characteristic blue-green color of copper(II) may be visible in the formulation.

Hair growth applications have used concentrations in the range of 0.01% to 0.1% in aqueous or hydroalcoholic scalp solutions. The evidence for hair growth promotion is more limited than for skin rejuvenation, but some studies have reported increased hair follicle size and proliferation of follicular keratinocytes with topical copper peptide application.

Application Frequency and Duration#

For anti-aging and skin rejuvenation, GHK-Cu products are typically applied once or twice daily to clean, dry skin. Morning and evening application is common in multi-step skincare routines. Visible improvements in skin texture, firmness, and fine wrinkle reduction have been reported in cosmetic studies after 8-12 weeks of consistent daily use.

For wound healing research applications, once or twice daily application directly to the wound surface has been employed in preclinical studies. The duration of treatment extends until wound closure is achieved or the study endpoint is reached.

For hair growth, once daily application to the scalp is the typical protocol. Given the long hair growth cycle (anagen phase lasts 2-6 years), longer treatment durations of 12-24 weeks are necessary to observe effects on hair density and quality.

pH and Vehicle Considerations#

The pH of the topical vehicle is a critical formulation parameter for GHK-Cu stability and efficacy. The optimal pH range for GHK-Cu is 5.5 to 6.5, which is consistent with the natural pH of healthy skin surface (approximately 4.5-5.5 for the acid mantle). At this pH:

• The copper-peptide complex remains intact and does not dissociate
• The peptide is chemically stable against hydrolytic degradation
• Skin barrier function is maintained, allowing gradual penetration
• The formulation is non-irritating to normal skin

At pH values below 4.0, protonation of the histidine imidazole and amide nitrogen atoms disrupts copper coordination, releasing free copper ions. Free copper is less effective biologically and more likely to cause irritation. At pH values above 8.0, copper hydroxide precipitation may occur.

The vehicle system also influences GHK-Cu delivery. Oil-in-water emulsions (creams and lotions) are the most common vehicle type for GHK-Cu products. The hydrophilic nature of GHK-Cu means it partitions preferentially into the aqueous phase of emulsions. To enhance skin penetration of this hydrophilic peptide through the lipophilic stratum corneum, several strategies have been explored:

Liposomal encapsulation: GHK-Cu incorporated into phospholipid liposomes shows improved skin penetration in in vitro diffusion studies compared with simple aqueous solutions. Liposomes facilitate passage through the lipid-rich intercellular spaces of the stratum corneum.

Microneedling enhancement: The combination of topical GHK-Cu with microneedling (dermal roller or automated microneedling devices) creates transient microchannels through the stratum corneum, dramatically increasing peptide delivery to the dermis. Some dermatological practices use GHK-Cu serums immediately following microneedling procedures.

Iontophoresis: Application of a low-level electric current can drive the positively charged GHK-Cu (net positive charge at skin pH) into the skin via electrophoretic and electroosmotic mechanisms. Iontophoresis has been explored in research settings but is not part of standard cosmetic use.

Nanoparticle delivery: Polymeric nanoparticles and solid lipid nanoparticles have been investigated as carriers for GHK-Cu, offering controlled release and improved stability in addition to enhanced penetration.

Topical Dosing Summary Table#

Subcutaneous Injection Dosing (Research Context)#

Subcutaneous injection of GHK-Cu is used in some research and self-experimentation contexts, though it is important to emphasize that this route is not supported by clinical trial data and GHK-Cu is not approved for injection use in any jurisdiction.

Practitioner protocols and community use typically describe doses of 1-2 mg administered once daily via subcutaneous injection. Some protocols use 3-5 injections per week rather than daily dosing. Cycling is common, with 4-8 weeks on followed by 2-4 weeks off. These doses are substantially higher than endogenous plasma concentrations of GHK (approximately 80-200 ng/mL), and the pharmacokinetics of injected GHK-Cu -- including copper distribution and clearance -- have not been formally characterized in human studies.

Reconstitution#

For injection use, GHK-Cu is typically supplied as a lyophilized (freeze-dried) powder that requires reconstitution before administration.

Reconstitution procedure:

1. Allow the vial of lyophilized GHK-Cu to reach room temperature
2. Using a sterile syringe, slowly add bacteriostatic water (preserved with 0.9% benzyl alcohol) or sterile water for injection to the vial
3. Direct the water stream along the side of the vial rather than directly onto the powder
4. Gently swirl the vial until the powder is fully dissolved; do not shake vigorously
5. The resulting solution should be clear and blue-tinged (characteristic of Cu(II))
6. If particles or cloudiness are present, do not use

Typical reconstitution volumes depend on the amount of GHK-Cu in the vial and the desired injection volume. For example, a 50 mg vial reconstituted with 2 mL of bacteriostatic water yields a 25 mg/mL solution. A 2 mg dose would then require 0.08 mL (8 units on a U-100 insulin syringe) of this solution.

Injection Sites and Technique#

Subcutaneous injection sites used in research protocols include:

• Abdominal subcutaneous tissue (alternating left and right of the umbilicus)
• Anterior thigh
• Upper arm (deltoid region)

Standard subcutaneous injection technique applies: clean the injection site with an alcohol swab, pinch a fold of skin, insert the needle at a 45-degree angle, inject slowly, and withdraw. Rotation of injection sites helps prevent localized tissue reactions.

Storage and Stability#

Lyophilized Powder#

Lyophilized GHK-Cu powder should be stored at -20 degrees C for long-term storage (months to years) or at 2-8 degrees C (refrigerated) for shorter periods (weeks to months). The powder should be protected from moisture, light, and repeated temperature fluctuations. Under appropriate storage conditions, lyophilized GHK-Cu maintains potency for 2-3 years.

Reconstituted Solution#

Once reconstituted, GHK-Cu solution should be refrigerated at 2-8 degrees C and used within 2 weeks. The use of bacteriostatic water extends the usable period by inhibiting microbial growth, but does not prevent peptide degradation. Signs of degradation include loss of blue color (indicating copper dissociation), precipitation, cloudiness, or color change to green or brown.

Topical Formulations#

Commercial GHK-Cu topical products are formulated for room temperature storage and typically have shelf lives of 12-24 months. They should be kept away from direct sunlight and excessive heat, which can accelerate both peptide degradation and copper-mediated oxidative reactions. Products should be discarded if they change color, develop an unusual odor, or show signs of separation.

Research vs. Cosmetic Dosing Context#

A critical distinction exists between GHK-Cu dosing in research versus cosmetic contexts. Cosmetic products are designed for safety and tolerability at the population level and contain concentrations that have been validated through cosmetic safety testing. Research dosing -- particularly for injection use -- is based on extrapolation from preclinical data and lacks the safety validation of controlled clinical trials.

The effective concentration of GHK-Cu at the target tissue (dermis, wound bed, or hair follicle) depends not only on the applied concentration but also on the delivery vehicle, application technique, skin condition, and duration of contact. Higher applied concentrations do not necessarily result in proportionally higher tissue levels, particularly for topical application where the stratum corneum serves as a rate-limiting barrier.

Evidence Gaps#

• No formal human dose-finding (Phase I/II) studies have been conducted for any route of administration
• Optimal topical concentration for maximal efficacy has not been determined in comparative controlled studies
• Pharmacokinetics after topical or subcutaneous administration in humans have not been published
• The relationship between applied dose, tissue concentration, and biological response is not characterized
• No head-to-head comparisons of different delivery vehicles or enhancement techniques have been published
• Long-term dosing safety beyond cosmetic study durations (8-16 weeks) is not established

Tools & Resources#

Calculate your exact dose -- Use the Dosing Calculator to convert vial concentrations to injection volumes for GHK-Cu.

Building a multi-peptide protocol? -- Try the Protocol Schedule Builder to plan your research timeline with GHK-Cu alongside other peptides.

Check stack compatibility -- Verify GHK-Cu interactions with your other peptides using the Stack Compatibility Checker.

Related Dosing Guides#

• BPC-157 Dosing Protocols -- Often stacked with GHK-Cu for enhanced tissue healing
• TB-500 Dosing Protocols -- Complementary tissue repair peptide
• Matrixyl Dosing -- Another skin-focused peptide for topical protocols

Compare GHK-Cu#

• GHK-Cu vs BPC-157 -- Healing peptide head-to-head
• GHK-Cu vs TB-500 -- Tissue repair comparison
• GHK-Cu vs Matrixyl -- Skin rejuvenation comparison

Related Reading#

• GHK-Cu overview and research guide
• GHK-Cu side effects profile
• GHK-Cu research evidence